A review of the efficacy and tolerability of venlafaxine

European Psychiatry

Volumn 12, Issue SUPPL. 4, 1997, Pages 307s-313s

  Dierick, M ^a  

^a Sint Camillus Psychiatric Hospital   (Belgium)

Author keywords

Major depression; SSRIs; Tricyclics; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGITATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MELANCHOLIA; MENTAL DEFICIENCY; NAUSEA; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; XEROSTOMIA;

EID: 0030750025     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(97)83310-X     Document Type: Article

References (31)

1. Bech P. A review of the antidepressant properties of serotonin reuptake inhibitors. Adv Biol Psychiatry 1988;17:58-69
2. Beasley CM, Jr, Bosomworth JC, Wernicke JF. Fluoxetine: relationship among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990;26:18-24
3. Benkert O, Gründer G, Wetzel, H, Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996;30: 441-51
4. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48
5. Clerc GE, Ruimy P, Verdeau-Pailles J, on behalf of the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-43
6. Cunningham LA, Borison RL, Carman JS et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106
7. Depression Guideline Panel. Depression in Primary Care: Volume 2. Treatment of Major Depression. Clinical Practice Guideline, Number 5. Rockville, MD. US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication NO 93-055, April 1993
8. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71
9. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992;53(suppl):21-6
10. Entsuah R, Upton GV, Rudolph R. Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: A meta-analysis. Hum Psychopharmacology 1995;10:195-200
11. Ferguson J, Khan A, Kucharik R et al. A placebo-controlled comparative study of the effects of blood pressure and antidepressant efficacy of venlafaxine and imipramine (abstract). Neuropsychopharmacology 1994;10(suppl): 165
12. Gründer G, Wetzel H, Schlosser R, Benkert O. Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24 hour monitoring. Pharmacopsychiatry 1996; 29:73-8
13. Guelfi JD, White C, Hackett D et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-8
14. Khan A, Rudolph R, Baumel B et al. Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharmacol Bull 1995;31:753-8
15. Lecable P, Letzelter J-M, Lichtblau E et al. An open label evaluation of the clinical acceptability of venlafaxine for general use as an antidepressant. Prim Care Psychiatry 1995;1: 45-51
16. Magni G, Hackett D. An open-label evaluation of the long-term safety and clinical acceptability of venlafaxine in depressed patients (abstract). Clin Neuropharmacology 1992;15(suppl 1, Pt B):323B
17. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of bid doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;29:169-74
18. Mendlewicz J. Pharmacologic profile and efficacy of venlafaxine. Int Clin Psychopharmacol 1995;10(suppl 2):5-14
19. Michels R, Marzuk PM. Progress in psychiatry. N Engl J Med 1993;329:628-38
20. Muth EA, Haskins JT, Moyer JA et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-97
21. Muth EA, Moyer JA, Haskins JT et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-9
22. Nierenberg A, Feighner JP, Rudolph R et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:19-423
23. Otton SV, Ball SE, Cheung SW et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41:149-56
24. Preskorn SH, Lane RM. Sertraline 50 mg: optimal dose in the treatment of depression. Int Clin Psychopharmacology 1995;10:129-41
25. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994;55(suppl):6-21
26. Rudolph R, Entsuah R, Derivan A. Early clinical response in depression to venlafaxine hydrochloride (abstract). Biol Psychiatry 1991;29:630S
27. Rudolph R, Entsuah R, Derivan A. A low relapse rate confirms the long-term efficacy of venlafaxine in the treatment of major depression (abstract). Neuropsychopharmacology 1994a;10(suppl):105
28. Rudorfer MV, Potter WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs. Drugs 1989;37:713-38
29. Samuelian JC, Tatossian A, Hackett D. A randomized, double-blind, parallel group comparison of venlafaxine and clomipramine in outpatients with major depression (abstract). Clin Neuropharmacology 1992;15(Suppl 1, Pt B):324B
30. Schweizer E, Feighner JP, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8
31. Shrivastava R, Cohn C, Crowder J et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994;14:322-9